Cancer du sein pendant la grossesse : enjeux cliniques et avancées thérapeutiques au sein du service d'oncologie médical de Bordj Bou Arreridj et au service d'oncologie médical anti cancer el BEZ à Sétif

Abstract

Although breast cancer during pregnancy is relatively rare in Algeria from a clinical standpoint, it is not exceptional, with an incidence of about 1 in 1000 pregnancies. Understanding the recommended management for a patient with cancer during pregnancy can provide insights into the challenges and obstacles encountered throughout this medical journey. A clinical analysis of records conducted within the medical oncology department of Bordj Bou Arreridj and the medical oncology department of Sétif, covering 7 cases of women suffering from breast cancer during and after pregnancy, aimed to evaluate the complex management of this pathology when a second life is at stake. The study reveals the relatively young average age of the patients, with an average of 37 years, and the majority of cases diagnosed during pregnancy (5 out of 7). Histological analysis shows a predominance of SBR grade III, although one case of SBR grade II suggests diversity in histological presentations. Assessments of hormone receptors and HER2 status indicate significant variability in these biological markers. Therapeutic management, in accordance with international recommendations, generally includes a combination of treatments such as surgery and chemotherapy (mainly in the second and third trimesters), while hormone therapy, radiotherapy, and targeted therapies are postponed to the postpartum period. Significant advances have been made in managing breast cancer during pregnancy in recent years, despite the challenges encountered at different stages of the management process. It is crucial to raise awareness among patients about the risks associated with a potential pregnancy during their treatment.